Literature DB >> 6110437

Investigation of a combined arteriolar dilator and beta-adrenoceptor antagonist (SK & F 92657) in the peripheral vessels of man.

J G Collier, D W Pitcher.   

Abstract

1 SK & F 92657 is a new compound which in animals has both precapillary vasodilator and beta-adrenoceptor blocking activity. The effects of the drug on forearm blood flow and dorsal hand vein distensibility have been studied in healthy volunteers. 2 Forearm blood flow was measured by venous occlusion plethysmography. The drug was infused directly into a brachial artery. The effects of SK & F 92657 on resting flow and on the dose-response relationship for intra-arterial isoprenaline were studied. 3 Venous distensibility was measured in the large veins on the back of the hand. The drug was infused directly into a selected vein and its effects on resting tone and on the responses to noradrenaline and to isoprenaline were investigated. 4 Intra-arterial infusion of SK & F 92657 over 2 min caused a dose-dependent increase in forearm blood flow which developed gradually to reach a maximum after approximately 40 min. Infusion into dorsal hand veins at 100 ng/min and 500 ng/min had no dilator effect in veins preconstricted with noradrenaline. At higher doses SK & F 92657 potentiated the constrictor effect of noradrenaline. 5 In both veins and arteries SK & F 92657 attenuated the dilator effects of isoprenaline. The drug had no effect on the venodilator effects of bradykinin, histamine or sodium nitroprusside. 6 The pattern of response of these vessels to locally infused SK & F 92657 is exactly that expected of a drug combining the properties of hydralazine-like vasodilatation and beta-adrenoceptor blockade. Furthermore, in the arterioles, both properties were manifest at the same dose.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6110437      PMCID: PMC1430227          DOI: 10.1111/j.1365-2125.1980.tb00512.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  The measurement of volume changes in human limbs.

Authors:  R J WHITNEY
Journal:  J Physiol       Date:  1953-07       Impact factor: 5.182

Review 2.  Compliance with antihypertensive drug therapy.

Authors:  D W Taylor; D L Sackett; R B Haynes; A L Johnson; E S Gibson; R S Roberts
Journal:  Ann N Y Acad Sci       Date:  1978-03-30       Impact factor: 5.691

3.  Effect of catecholamines and other vasoactive substances on superficial hand veins in man.

Authors:  J G Collier; C Nachev; B F Robinson
Journal:  Clin Sci       Date:  1972-09       Impact factor: 6.124

4.  Simplified method for measuring compliance of superficial veins.

Authors:  C Nachev; J Collier; B Robinson
Journal:  Cardiovasc Res       Date:  1971-01       Impact factor: 10.787

5.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

6.  An assessment of beta-adrenoceptor blockade in man by SK & F 92657, a new drug with combined vasodilator and beta-adrenoceptor blocking actions, and comparison with propranolol [proceedings].

Authors:  D W Pitcher; P V Curry; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

7.  SK&F 92657, a novel antihypertensive acting by precapillary vasodilatation and beta-adrenoreceptor blockade.

Authors:  E M Taylor; A M Roe; R A Slater
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

8.  Effects of propranolol on peripheral vessels in man.

Authors:  I Brick; W E Glover; K J Hutchison; I C Roddie
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

  8 in total
  7 in total

1.  Comparison of the effects of prizidilol and propranolol on renal haemodynamics at rest and during exercise.

Authors:  P L Malini; E Strocchi; E Ambrosioni
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

2.  Cardiovascular effects in man of intravenous prizidilol hydrochloride (SK&F 92657); a new antihypertensive agent.

Authors:  W M Edmonstone; K K Manghani; A J Bell; M McLeod; G J Milton-Thompson; W L Burland
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

3.  An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride.

Authors:  D W Pitcher; P V Curry; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

4.  Comparison of prizidilol hydrochloride (SK & F 92657), a new antihypertensive agent with beta-adrenoceptor antagonist and vasodilator activity with propranolol and hydralazine in normal volunteers.

Authors:  J A Steiner; A Clancy; K K Manghani; I M James
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

5.  Metal binding by pharmaceuticals. Part 4. A comparative investigation of the interaction of metal ions with hydralazine, prizidilol and related compounds.

Authors:  H Al-Falahi; P M May; A M Roe; R A Slater; W J Trott; D R Williams
Journal:  Agents Actions       Date:  1984-01

6.  Pulmonary effects in man of oral prizidilol hydrochloride (SK&F 92657), a new antihypertensive agent.

Authors:  W M Edmondstone; J F Waller; K K Manghani; P L Hill; A J Bell; D M Denison
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

7.  Cardiovascular response to exercise and regional haemodynamics during treatment with prizidilol hydrochloride (SK & F 92 657) in moderately severe essential hypertension.

Authors:  O Andersson; S Ljungman; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.